sales@towardshealthcare.com
+1 804-441-9344
February 2026
The Parkinson’s disease diagnosis and treatment market is expected to increase from USD 7.49 billion in 2025 to USD 17.57 billion by 2035, growing at a CAGR of 8.9% throughout the forecast period from 2026 to 2035.
| Key Elements | Scope |
| Market Size in 2026 | USD 8.16 Billion |
| Projected Market Size in 2035 | USD 17.57 Billion |
| CAGR (2026 - 2035) | 8.9% |
| Leading Region | North America |
| Market Segmentation | By Diagnosis, By Treatment, By Geography |
| Top Key Players | Siemens Healthineers AG, Abbott Laboratories, General Electric Company, AbbVie, Merck & Co., Pfizer, Teva Pharmaceutical Industries Ltd., Sun Pharma, Novartis AG, Cerevel Therapeutics |
"According to Parkinson’s News Today, about 41 out of every 100,000 people in their 40s are affected by Parkinson’s disease. This number increases to more than 1,900 out of every 100,000 for people in their 80s and 90s. Parkinson's is the second most common neurodegenerative disorder, after Alzheimer’s disease. Right now, there's no cure for Parkinson's, and people with the condition need lifelong medication support."
Parkinson's disease is a neurological disorder characterized by involuntary movements such as tremors, stiffness, and difficulty with coordination. Symptoms usually develop gradually and worsen over time, affecting mobility, speech, and cognition. While the exact cause is unclear, research suggests a combination of genetic and environmental factors may contribute to the disease's onset. Parkinson's primarily affects the basal ganglia in the brain, leading to a decrease in dopamine production and subsequent movement problems. Despite ongoing research, the exact reasons for nerve cell death in Parkinson's remain unknown.
Parkinson's has four major symptoms:
There is a lot of interest in finding a treatment that will help slow the progression of Parkinson's disease. These are known as neuroprotective or disease-modifying drugs. The idea is based on the notion that dopamine-producing neurons can be protected from premature death and dopamine depletion.
At this point, no treatment is neuroprotective. Numerous treatments have been investigated, including MAO-B inhibitors, dopamine agonists, coenzyme Q10, and vitamin E. There is insufficient evidence to conclude that these therapies are beneficial, and they are not currently recommended to slow the Parkinson's disease. Several clinical trials are being conducted to identify disease-modifying drugs.
It's really important to find out if someone has Parkinson's early and give them the right treatment. This can help them manage their symptoms better and have a better quality of life.
Parkinson's disease (PD) is a condition that affects the brain and causes problems with movement, like shaking, stiffness, and slow movements. It's becoming more common worldwide, especially in places where people are living longer lives. As more people get older, the number of those diagnosed with PD goes up.
For instance,
With more people getting Parkinson's, there's a bigger need for tools to help doctors find out if someone has it. These tools include things like scans and tests that can see inside the brain to spot signs of PD. When PD is detected early, doctors can start treatment sooner, which can help manage symptoms better and improve quality of life.
Alongside diagnosis, there's also a growing demand for treatments. Medicines that help control PD symptoms are becoming more important. These drugs can help reduce shaking, stiffness, and other issues caused by Parkinson's, allowing people to live more comfortably.
But it's not just about medicines. As Parkinson's progresses, people often need additional support. This includes therapies like physical therapy to keep muscles strong and occupational therapy to assist with everyday tasks. With more attention on Parkinson's disease, there's also more focus on research. Scientists are working hard to understand the disease better and develop new treatments. This research leads to discoveries that can improve the lives of those with PD.
A study supported by the Parkinson's Foundation in 2022 found that around 90,000 individuals receive a diagnosis of Parkinson's disease in the United States every year. This marks a significant 50% rise from the earlier estimated figure of 60,000 diagnoses per year. Advancements in treating Parkinson's disease (PD) are making a big impact on the market for PD diagnosis and treatment. Imagine you have a toolbox, and every time you find a new tool that works better, more people want to use it. That's what's happening with PD treatments. Infusion therapy, which delivers medicine directly into the body. These treatments offer new options for managing PD symptoms and improving quality of life.
As more effective treatments become available, more people are seeking help. This increased demand for treatment options is driving growth in the PD market. Companies that make these treatments can sell more products and invest more in research to make even better treatments in the future. But it's not just about treatments – better diagnosis tools are also making a difference. When doctors can identify PD earlier, they can start treatment sooner, which can slow down the progression of the disease and improve outcomes for patients.
Diagnosing Parkinson's disease early on can be tough because its symptoms aren't always obvious and can resemble those of other health problems. Sometimes, individuals may not even realize they have Parkinson's because the signs are subtle. This makes it hard for doctors to identify the disease quickly and start the right treatment. It's like trying to find the right answer in a big book with lots of similar-looking pages – you need time to carefully examine each one to find the correct information. Similarly, doctors need time and specific tests to carefully study the symptoms and confirm if it's Parkinson's. Getting an early diagnosis is important because it lets doctors begin treatment sooner. Starting treatment early can help manage symptoms more effectively and improve the person's quality of life.
Which Diagnosis Segment Dominated the Parkinson’s Disease Diagnosis and Treatment Market?
The imaging tests segment held a dominant position in the market in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period, due to the need to study disease progression and detect the stage of disease. Imaging techniques, such as brain ultrasound, SPECT, and PET, are commonly used to detect PD. Advanced technologies like AI and ML are embedded in imaging tools to facilitate the detection of minute changes that are difficult to diagnose by humans. They enhance the accuracy and precision of diagnosis. Some emerging imaging tests include fluorodeoxyglucose PET, fluorodopa PET, transcranial sonography, and alpha-synuclein imaging.
Why Did the Medications Segment Dominate the Parkinson’s Disease Diagnosis and Treatment Market?
The medications segment dominated the market in 2025, due to high cost-effectiveness and ease of administration. Medications are the first line of agents for treating PD of early to late stages. They help manage symptoms by increasing or substituting dopamine in the brain. Out of all mediations, carbidopa-levodopa is the most widely used drug combination in patients with PD. Moreover, researchers focus on developing novel drug delivery systems to deliver the drug directly into the brain and cross the blood-brain barrier.
The deep brain stimulation segment is expected to expand rapidly in the forecast period. Advancements in medical technology, such as deep brain stimulation (DBS) and infusion therapies, are aiding individuals with Parkinson's disease (PD) by offering innovative treatment options. Deep brain stimulation involves implanting tiny electric wires in the brain to manage PD symptoms, while infusion therapies deliver medication directly into the body. These advancements contribute to improving patient care. The total cost of Parkinson's disease in the United States, covering treatment expenses, social security aid, and lost income, is estimated to be around $52 billion annually.
These innovations are a big deal because they expand the choices for treating PD. Before, there weren't as many options, but now doctors and patients have more to choose from. This means better outcomes for patients – their symptoms can be managed more effectively, helping them feel better and live more comfortably.
For instance,
North America is home to leading pharmaceutical companies, biotechnology firms, and academic research institutions that are actively engaged in developing new therapies, diagnostic tools, and disease-modifying treatments for Parkinson's disease. North America has a significant aging population, with a large proportion of individuals aged 65 and older. As PD is more common in older adults, this demographic trend contributes to the prevalence of the disease in the region. The regulatory landscape in North America, particularly in the United States and Canada, plays a crucial role in shaping the market for PD diagnosis and treatment. Approval processes for new drugs, medical devices, and treatment modalities impact market entry and commercialization strategies.
U.S. Market Trends
The presence of a robust healthcare infrastructure and favorable government support contributes to market growth in the U.S. The Food and Drug Administration (FDA) regulates the approval of drugs and medical devices for PD. It has approved a total of 29 medications for PD treatment. PD affects approximately 1.1 million people in the U.S. annually.
The Asia-Pacific region is home to a diverse population, including both rapidly aging populations in countries like Japan and South Korea and younger populations in countries like India and Indonesia. The increasing prevalence of Parkinson's disease, particularly in aging populations, drives demand for diagnosis and treatment options. Research and development activities in Parkinson's disease diagnosis and treatment are gaining traction in the Asia-Pacific region, with academic institutions, healthcare organizations, and pharmaceutical companies collaborating to address unmet medical needs and develop innovative solutions.
China Market Trends
China is emerging as a global hub in conducting clinical trials with a favorable regulatory framework and an increasing patient population. As of 2025, 333 trials were registered on the clinicaltrials.gov website related to PD in China. The burden of PD is increasing in China owing to the growing geriatric population. More than one-fifth of the total Chinese population is older than 60 years.
Europe is considered to be a significantly growing area, due to the increasing prevalence of PD, favorable government support, and the rising adoption of advanced technologies. Over 1 million Europeans are estimated to be affected by PD, and this number is projected to double by 2030. Government and private institutions organize seminars, workshops, and conferences to share the latest updates about PD diagnosis and treatment. The European government launched the AI-PROGNOSIS to improve PD diagnosis and care.
France Market Trends
The French government has recently launched a national neurodegenerative strategy 2025-2030 to support around 1.5 million people living with neurodegenerative diseases in France. In March 2025, the NS-PARK clinical research network launched Master Trial, the first French clinical trial platform to accelerate the identification of neuroprotective treatments for PD.
The Middle East & Africa are expected to grow at a notable CAGR in the foreseeable future. The rising prevalence of PD, increasing R&D investments, and growing demand for personalized medicines augment the market. The region is establishing a suitable research and manufacturing infrastructure to allow foreign companies to set up their facilities and serve the local population. The rising public-private partnership and growing research activities also contribute to market growth.
UAE Market Trends
Cleveland Clinic Abu Dhabi, King’s College Hospital London in Dubai, and CMC Dubai are some clinics that provide PD diagnosis and treatment in the UAE. The region recently launched the first mobile clinic to offer free consultations for patients suffering from PD, promoting a healthy lifestyle and offering advice to patients.
Latin America is considered to be a significantly growing area, due to the increasing awareness of neurological conditions and favorable government initiatives. Government bodies encourage the general public to screen for and seek early diagnosis of neurological disorders, enabling healthcare professionals to provide early intervention. They also make constant efforts to enhance rural access to PD diagnosis and treatment.
For instance,
Brazil Market Trends
The growing geriatric population is a major concern, potentiating the risk of PD in the region. It is estimated that approximately 3.3% of people aged 65 years and above have PD in Brazil. The increasing research and clinical trials in the region also fosters market growth. As of 12th January 2026, a total of 84 clinical trials were registered in Brazil related to PD.
By Diagnosis
By Treatment
By Geography
February 2026
February 2026
February 2026
February 2026